Orphan Medicinal Product Regulation. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J. 2000;L 18:15.
Google Scholar
European Commission [Internet]. Brussels: Directorate-General for Health and Food Safety [cited 2015 Mar 20]. Available from: http://ec.europa.eu/health/rare_diseases/policy/.
Editorial. Rare neurological diseases: a united approach is needed. Lancet Neurol. 2011;10(2):109.
Van Haren K, Waubant E. Therapeutic advances in pediatric multiple sclerosis. J Pediatr. 2013;163(3):631–7.
Article
PubMed
Google Scholar
Orphanet [Internet]. Paris [updated 2015 July]. [cited 2015 Aug 7]. Available from: http://www.orpha.net.
Kornek B. Treatment of pediatric multiple sclerosis. Neuropediatrics. 2013;44:309–13.
Article
CAS
PubMed
Google Scholar
National Multiple Sclerosis Society [Internet]. New York City [cited 2015 Apr 21]. Available from: http://www.nationalmssociety.org/.
Orphanet Report Series. Prevalence of rare diseases: bibliographic data, vol. 1. 2014.
Google Scholar
Creutzfeldt-Jakob disease fact sheet. National Institute of Neurological Disorders and Stroke. Bethesda, MD [cited 2015 Apr 21]. Available from: http://www.ninds.nih.gov/disorders/cjd/detail_cjd.htm.
Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014;95:265–8.
Article
CAS
PubMed
Google Scholar
De la Paz MP, Villaverde-Hueso A, Alonso V, János S, Zurriaga O, Pollán M, et al. Rare diseases epidemiology research. Adv Exp Med Biol. 2010;686:17–39.
Article
PubMed
Google Scholar
European Medicines Agency (EMA). Guideline on clinical trials in small populations. London:European Medicines Agency; 2006.
Korn EL, Freidlin B. Outcome-adaptive randomization: Is it useful? J Clin Oncol. 2011;29(6):771–6.
Article
PubMed Central
PubMed
Google Scholar
Johannessen T. Controlled trials in single subjects. 1. Value in clinical medicine. BMJ. 1991;303(6795):173–4.
Article
PubMed Central
CAS
PubMed
Google Scholar
Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: Wiley; 2004.
Google Scholar
Food and Drug Administration (FDA). Rare diseases: common issues in drug development. Draft guidance for industry. Silver Spring, Maryland:Food and Drug Administration; 2015.
Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802.
Article
PubMed Central
PubMed
Google Scholar
Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med. 2013;5(178):178sr3.
Article
PubMed
Google Scholar
Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8:48.
Article
PubMed Central
PubMed
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. J Clin Epidemiol. 2009;62:1006–12.
Article
PubMed
Google Scholar
Wieseler B, McGauran N. Reporting a systematic review. Chest. 2010;137(5):1240–6.
Article
PubMed
Google Scholar
Higgins JPT, Altman DG, Sterne, JAC (editors). Chapter 8: Assessing risk of bias in included studies. In Higgins JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://www.cochrane-handbook.org.
Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from: http://www.cochrane-handbook.org.
Google Scholar
Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. Neurology. 2009;72:8–10.
Article
PubMed
Google Scholar
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
Article
CAS
PubMed
Google Scholar
Bykova OV, Studenikin VM, Kuzenkova LM, Maslova OI, Boĭko AN. Effective treatment of multiple sclerosis with rebif-22 mcg in children and adolescences: results of a long-term study. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Spec No 3:116–21.
CAS
PubMed
Google Scholar
Bykova OV, Kuzenkova LM, Maslova OI. The use of beta-interferon-1b in children and adolescents with multiple sclerosis. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(9):29–33.
CAS
PubMed
Google Scholar
Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics. 2006;37(4):257–60.
Article
CAS
PubMed
Google Scholar
Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009;30(3):193–9.
Article
PubMed
Google Scholar
Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci. 2007;28(3):127–32.
Article
CAS
PubMed
Google Scholar
Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci. 2005;26 Suppl 4:S183–6.
Article
PubMed
Google Scholar
Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005;11(4):420–4.
Article
CAS
PubMed
Google Scholar
Day SJ, Graham DF. Sample size and power for comparing two or more treatment groups in clinical trials. BMJ. 1989;299(6700):663–5.
Article
PubMed Central
CAS
PubMed
Google Scholar
Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013;28(7):849–56.
Article
PubMed
Google Scholar
Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472–6.
Article
CAS
PubMed
Google Scholar
Pohl D, Rostasy K, Gärtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64(5):888–90.
Article
CAS
PubMed
Google Scholar
Mikaeloff Y, Caridade G, Tardieu M, Suissa S, KIDSEP study group of the French Neuropediatric Society. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol. 2008;12(3):205–9.
Article
PubMed
Google Scholar
Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double blind study. Neurology. 2004;62(5):714–8.
Article
CAS
PubMed
Google Scholar
Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81(23):2015–23.
Article
PubMed Central
CAS
PubMed
Google Scholar
Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334–44.
Article
PubMed Central
CAS
PubMed
Google Scholar
Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, et al. Doxycycline in Creutzfeldt–Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150–8.
Article
PubMed
Google Scholar
Collett D. Modelling survival data in medical research. 3rd ed. Boca Raton: Chapman & Hall/CRC; 2015.
Google Scholar
Tagliavini F. Prion therapy: tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease. Alzheimers Dement. 2008;4(suppl):T149–50.
Article
Google Scholar
Haïk S, Brandel JP, Salomon D, Sazdovitch V, Delasnerie-Lauprêtre N, Laplanche JL, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63(12):2413–5.
Article
PubMed
Google Scholar
Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18(1):116–27.
Article
CAS
PubMed
Google Scholar
Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347:f6409.
Article
PubMed
Google Scholar
Evans CH Jr, Ildstad ST, editors. Small Clinical Trials: Issues and Challenges. Washington, D. C.:National Academies Press; 2001.
Tenembaum SN. Ethical challenges in paediatric clinical trials in multiple sclerosis. Ther Adv Neurol Disord. 2012;5(3):139–46.
Article
PubMed Central
CAS
PubMed
Google Scholar
EMA [Internet]. London. [cited 2015 July 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500143702.pdf.
O’Hagan A, Buck CE, Daneshkhah A, et al. Uncertain judgements: Eliciting Experts’ Probabilities. Chichester: Wiley; 2006.
Book
Google Scholar
Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Stat Med. 2014;33(24):4186–201.
Article
PubMed Central
PubMed
Google Scholar
Goodman SN, Sladky JT. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barré syndrome. Clin Trials. 2005;2(4):305–10.
Article
PubMed
Google Scholar
European Medicines Agency (EMA). Concept paper on extrapolation of efficacy and safety in medicine development. London:European Medicines Agency; 2012.
Food and Drug Administration (FDA). Leveraging existing clinical data for extrapolation to pediatric uses of medical devices. Draft guidance. Silver Spring, Maryland:Food and Drug Administration; 2015.
Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705–13.
Article
CAS
PubMed
Google Scholar
Gross O, Friede T, Hilgers R, Görlitz A, Gavénis K, Ahmed R, et al. Safety and efficacy of the ace-inhibitor ramipril in alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT alport trial in pediatric patients. ISRN Pediatr. 2012;2012:436046.
Article
PubMed Central
PubMed
Google Scholar
Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Krasnianski A, et al. Doxycycline in early Creutzfeldt-Jakob disease – double-blinded randomized phase II and observational study. 2015. Submitted for publication.
Google Scholar
Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE. Evidence synthesis for decision making in healthcare. Chichester: Wiley; 2012.
Book
Google Scholar
Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials. 2010;7:5–18.
Article
PubMed
Google Scholar
Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013;19(8):1106–12.
Article
CAS
PubMed
Google Scholar
Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. 2013;70(4):469–75.
Article
PubMed
Google Scholar
Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67(3):511–3.
Article
CAS
PubMed
Google Scholar
Fincke F. Doxycyclin bei der sporadischen Creutzfeldt-Jakob-Krankheit. PhD thesis. Goettingen:University Medical Center Goettingen; 2010.